NASDAQ · LGND
Ligand Pharmaceuticals Incorporated
$317.33-$1.45 (-0.45%)
Ligand Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
Loading market information…
NYSE · EVMN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evommune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evommune, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $22.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$317.33-$1.45 (-0.45%)
Ligand Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
$23.14-$2.75 (-10.61%)
Fortrea Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.56% below the high.
$28.71-$0.19 (-0.66%)
Zymeworks Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.39% below the high.
$27.98+$0.47 (+1.71%)
Galapagos N.V.’s quoted price sits in the lower half of its reported 52-week range, 25.94% below the high.
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
$10.33+$0.21 (+2.08%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 43.64% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$1.22-$0.04 (-3.17%)
Codexis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
